Literature DB >> 22256481

Detection of alveolar rhabdomyosarcoma in pleural fluid with immunocytochemistry on cell block and determination of PAX/FKHR fusion mRNA by reverse transcription-polymerase chain reaction.

Ruchchadol Sawangpanich1, Noppadol Larbcharoensub, Artit Jinawath, Atcharaporn Pongtippan, Usanarat Anurathapan, Suradej Hongeng.   

Abstract

BACKGROUND: Alveolar rhabdomyosarcoma is a primitive malignant round cell neoplasm, which shows skeletal muscle differentiation. Although their histopathologic and immunohistochemical findings are well known, the cytology, immunocytochemistry and molecular study on pleural effusion have not been well documented.
OBJECTIVE: To apply molecular method in the diagnosis and monitoring of alveolar rhabdomyosarcoma. CASE REPORT: The case of a 14-year-old Thai male, who presented with dyspnea and left pleural effusion. Computed tomography of the chest and abdomen showed a huge heterogeneous enhancing mass at the left retroperitoneum. Pleural fluid cytology showed malignant small round blue cells. Immunocytochemical stains on cell block material showed positive reactivity to vimentin, sarcomeric actin, desmin, MyoD1, myogenin, and CD56 in round cell tumor Reverse transcription-polymerase chain reaction (RT-PCR) demonstrated PAX/FKHR fusion transcript. The patient received chemotherapeutic regimen for advanced-stage rhabdomyosarcoma. Finally, he succumbed to the disease, thirteen months after the diagnosis.
CONCLUSION: Immunocytochemistry on cell block in conjunction with determination of PAX/FKHR fusion mRNA by RT-PCR is a molecular method in the diagnosis and monitoring of alveolar rhabdomyosarcoma inpleural fluid.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22256481

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Cytological diagnosis of metastatic alveolar rhabdomyosarcoma in the ascitic fluid: Report of a case highlighting the diagnostic difficulties.

Authors:  Andrew C Nelson; Charanjeet Singh; Stefan E Pambuccian
Journal:  Cytojournal       Date:  2012-03-31       Impact factor: 2.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.